These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9756414)

  • 1. Human tumor cells, modified by a novel pressure/crosslinking methodology, promote autologous lymphocyte proliferation and modulate cytokine secretion.
    Eisenthal A; Goldman Y; Skornick Y; Gelfand A; Buyaner D; Kaver I; Yellin A; Yehoshua H; Lifschitz-Mercer B; Gonnene A; Shinitzky M
    Cancer Immunol Immunother; 1998 Aug; 46(6):304-10. PubMed ID: 9756414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma.
    Hinkel A; Tso CL; Gitlitz BJ; Neagos N; Schmid I; Paik SH; deKernion J; Figlin R; Belldegrun A
    J Immunother; 2000 Jan; 23(1):83-93. PubMed ID: 10687141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
    Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
    J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
    Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
    Finke JH; Rayman P; Hart L; Alexander JP; Edinger MG; Tubbs RR; Klein E; Tuason L; Bukowski RM
    J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):91-104. PubMed ID: 7907918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
    Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
    J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.
    Wittig B; Märten A; Dorbic T; Weineck S; Min H; Niemitz S; Trojaneck B; Flieger D; Kruopis S; Albers A; Löffel J; Neubauer A; Albers P; Müller S; Sauerbruch T; Bieber T; Huhn D; Schmidt-Wolf IG
    Hum Gene Ther; 2001 Feb; 12(3):267-78. PubMed ID: 11177563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
    Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
    Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
    Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
    J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
    J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
    Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
    Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of three commercial sweeteners on cytokine expression by mononuclears impelled by colon carcinoma cells.
    Bessler H; Djaldetti M
    Int J Food Sci Nutr; 2019 Dec; 70(8):970-976. PubMed ID: 31066319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma.
    Zelle-Rieser C; Barsoum AL; Sallusto F; Ramoner R; Rohrer JW; Höltl L; Bartsch G; Coggin JH JR; Thurnher M
    J Urol; 2001 May; 165(5):1705-9. PubMed ID: 11342960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
    Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
    Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor-immune system interaction in renal cell carcinoma and melanomas. Cytokine transcription in tumors at the time of surgical resection].
    Zuber M; Filgueira L; Merlo A; Lüscher U; Juretic A; Spagnoli G; Harder F; Heberer M
    Schweiz Med Wochenschr; 1994 Jun; 124(22):930-5. PubMed ID: 8029672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
    Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
    J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.